<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708344</url>
  </required_header>
  <id_info>
    <org_study_id>IRBEH_R_02931</org_study_id>
    <nct_id>NCT00708344</nct_id>
  </id_info>
  <brief_title>ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination</brief_title>
  <acronym>ACTUAL</acronym>
  <official_title>Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination: A Comparison of Active and Usual Titration Regimen in the Treatment of Hypertensive Patients Insufficiently Controlled by Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide
      (HCTZ) using either a usual or an active elective titration regimen. The main efficacy
      criteria will be the change in mean Systolic Blood Pressure (SBP), measured at doctor's
      office with an automatic device, after a 10-week treatment period in hypertensive patients
      insufficiently controlled by monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean Systolic Blood Pressure</measure>
    <time_frame>between Visit 1 (Week 0) and Visit 4 (Week 10)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in mean Diastolic Blood Pressure</measure>
    <time_frame>between Visit 1 (Week 0) and Visit 4 (Week 10)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">832</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual elective titration regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active elective titration regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan - Hydrochlorothiazide</intervention_name>
    <description>150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan - Hydrochlorothiazide</intervention_name>
    <description>150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Established essential hypertension treated for at least 4 weeks by one
             antihypertensive drug alone

          -  With uncontrolled Blood Pressure (BP) defined as:

          -  SBP ≥ 160 mmHg and/or DBP ≥ 100 mmHg in non diabetic patients

          -  SBP ≥ 150 mmHg and/or DBP ≥ 90 mmHg in diabetic patients

        Exclusion Criteria:

          -  SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg at V1

          -  Known or suspected causes of secondary hypertension

          -  Patient with bilateral renal artery stenosis, renal artery stenosis in a solitary
             kidney; history of renal transplant or only has one functioning kidney

          -  Associated cardiovascular conditions that prevent the patient from stopping the
             current antihypertensive drug (e.g.: Beta-blocker for angina, ACE-inhibitors for heart
             failure, etc…).

          -  Known hypersensitivity to diuretics or sulphonamides or history of angioedema or cough
             related to the administration of an angiotensin II receptor antagonist or any
             combination of the drugs used

          -  Known contraindications to the study drugs:

          -  Severe renal dysfunction (creatinine clearance &lt;30ml/min)

          -  Known hypokaliemia (&lt; 3 mmol/L) , known hypercalcemia

          -  Severe hepatic impairment, biliary cirrhosis, cholestasis

          -  Inability to obtain a valid automatic BP measurement recording

          -  Administration of any other investigational drug within 30 days prior to study entry
             and during the course of the study

          -  Presence of any severe medical or psychological condition that, in the opinion of the
             investigator, indicate that participation in the study is not in the best interest of
             the subject.

          -  Presence of any other conditions (e.g. geographic, social, etc) that would restrict or
             limit the subject participation for the duration of the study.

          -  Pregnant or breast-feeding women

          -  Women of childbearing potential not protected by effective contraceptive method of
             birth control

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathalie - GENES, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Algiers</city>
        <country>Algeria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Bogota</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Col. Coyoacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Casablanca</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Megrine</city>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Dubaï</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Caracas</city>
        <country>Venezuela</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Algeria</country>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Ecuador</country>
    <country>Egypt</country>
    <country>Guatemala</country>
    <country>Lebanon</country>
    <country>Mexico</country>
    <country>Morocco</country>
    <country>Panama</country>
    <country>Peru</country>
    <country>Saudi Arabia</country>
    <country>Tunisia</country>
    <country>United Arab Emirates</country>
    <country>Venezuela</country>
  </location_countries>
  <removed_countries>
    <country>Costa Rica</country>
  </removed_countries>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>July 15, 2010</last_update_submitted>
  <last_update_submitted_qc>July 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

